RhumbLine Advisers’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
Other funds holding CTKB
RhumbLine Advisers's CTKB Position: Q3 2026 in Review
RhumbLine Advisers increased its Cytek Biosciences (CTKB) stake by 8.5% in Q3 2026, buying an estimated $61.5K and bringing the position to 166,196 shares worth $991K. The position accounts for ﹤0.01% of the portfolio, ranked #2276.
RhumbLine Advisers first reported a position in CTKB in Q3 2021 and has held it in 21 quarters since. The position peaked at $2.99M in Q4 2023. 150 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.
- RhumbLine Advisers held 166,196 shares of Cytek Biosciences worth $991K as of Q3 2026.
- RhumbLine Advisers bought 12,971 Cytek Biosciences shares in Q3 2026, an estimated $61.5K.
- Cytek Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2276 holding.
- RhumbLine Advisers first reported a position in Cytek Biosciences in Q3 2021 and has held it in 21 quarters since.
- RhumbLine Advisers's Cytek Biosciences position peaked at $2.99M in Q4 2023.
- 150 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.